Neurogene Stock (NASDAQ:NGNE)

Forecast Ownership Financials Chart

Previous Close

$28.01

52W Range

$14.65 - $37.27

50D Avg

$26.74

200D Avg

$22.87

Market Cap

$458.26M

Avg Vol (3M)

$159.10K

Beta

2.04

Div Yield

NGNE Company Profile

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

107

IPO Date

Mar 07, 2014

Website

NGNE Performance

NGNE Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$925.00K	-
Operating Income	$-103.21M	$-82.61M	$-55.58M
Net Income	$-90.35M	$-75.14M	$-36.32M
EBITDA	$-103.33M	$-71.89M	$-52.29M
Basic EPS	$-4.24	$-4.28	$-2.83
Diluted EPS	$-4.24	$-4.28	$-2.83

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
FULC	Fulcrum Therapeutics, Inc.
PRTC	PureTech Health plc
AUTL	Autolus Therapeutics plc
QSI	Quantum-Si incorporated
ADCT	ADC Therapeutics S.A.
SLDB	Solid Biosciences Inc.
OCGN	Ocugen, Inc.
ALMS	Alumis Inc. Common Stock
BNTC	Benitec Biopharma Inc.